Vaginal microbiome testing market expands amid clinical warnings over biohacking metrics
A viral post by tech entrepreneur Bryan Johnson rating his partner’s vaginal microbiome has spotlighted the rapid commercialisation of women’s health data, raising concerns among medical experts about reductive scoring systems in a fast-growing market.
In spring 2026, tech entrepreneur Bryan Johnson published his partner’s vaginal microbiome test results online, claiming the score placed her in the "top 1% of all vaginas." The post generated over 21 million views within 48 hours, marking a viral moment for the intersection of biohacking culture and women’s health.
This spectacle arrives as the vaginal microbiome testing sector experiences rapid financial growth. The market reached $159.99 million in 2025 and is projected to hit $250.05 million by 2030, representing a compound annual growth rate of 9.34 per cent.
This niche sits within a much larger feminine intimate care ecosystem, which was valued at $7.8 billion in 2024 and is expected to reach $14 billion by 2034. Investors are heavily backing companies aiming to close historical data gaps in women’s health through advanced sequencing and artificial intelligence.
The score Johnson cited measures the dominance of Lactobacillus crispatus, a bacterium linked to lower risks of bacterial vaginosis, high-risk HPV persistence, and preterm birth. However, medical professionals warn that converting this biological marker into a percentile ranking is a marketing tactic rather than a clinical standard.
Board-certified urogynecologist Dr Michael Ingber noted that healthcare providers do not use such scoring terms clinically. He emphasised that the vaginal microbiome is highly dynamic, shifting with menstruation, sexual activity, antibiotics, and hormonal changes, meaning a single score cannot comprehensively measure health or fertility.
Experts also warn that these commercial metrics risk pathologising normal human diversity. Research indicates that Black women, on average, have higher microbial diversity and lower abundance of L. crispatus than white women, while Asian women generally show the highest percentage of Lactobacillus-dominant profiles.
Dr Betsy Greenleaf, a urogynecologist, cautioned that laboratory normal ranges are often just statistical averages of the populations historically included in research datasets. She warned that failing to acknowledge natural variability risks suggesting one microbiome profile is superior simply because it reflects an overrepresented demographic.
Companies in the space acknowledge these limitations and the need for diverse data. Priyanka Jain, chief executive of testing firm Evvy, stated that the science is more nuanced than a viral tweet can hold. Her company, which raised $14 million in Series A funding in 2023, emphasises building large-scale datasets to avoid repeating historical medical biases.
Ultimately, while at-home testing can improve access to valuable health data, the commodification of intimate biology into trackable performance metrics remains fraught. As the sector scales, the challenge for investors and regulators will be ensuring that commercialisation does not outpace scientific interpretation and equitable care.
